BSEParmax Pharma LtdMediumNeutral
Announced Thu, 2 Oct · 20:31 IST

Voting Result along with scrutinizer report for 31st AGM of the COmpany

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Parmax Pharma held its 31st AGM on September 30, 2025 at its registered office in Rajkot, Gujarat (03:30 PM to 03:54 PM). Three ordinary resolutions were put to vote via remote e-voting (Sept 27–29) and physical poll: (1) adoption of audited financial statements for FY ended March 31, 2025 — passed with 99.9999% in favor; (2) re-appointment of Mr. Umang Alkesh Gosalia (Managing Director, DIN: 05153830) as Director retiring by rotation — passed with 99.9996% in favor; (3) appointment of Mr. Samsad Alam Khan as Secretarial Auditor — passed with 99.9999% in favor. Of the 37,41,300 total outstanding shares, only about 31% were polled. The promoter group holding 11,52,450 shares (~30.8%) did not vote on any resolution, while 15 public shareholders attended in person. Scrutinizer Samsad Alam Khan certified the e-voting process as fair and transparent.

Likely market impact

This is a routine regulatory filing confirming that all AGM resolutions passed with overwhelming shareholder support. The notable observation is the promoter group's non-participation in voting despite holding a meaningful stake, though this does not affect the validity of the resolutions. No material impact on share price is expected.